Market Cap 1.76B
Revenue (ttm) 528.30M
Net Income (ttm) -56.11M
EPS (ttm) N/A
PE Ratio 190.33
Forward PE 380.67
Profit Margin -10.62%
Debt to Equity Ratio 2.02
Volume 4,149,300
Avg Vol 5,070,182
Day's Range N/A - N/A
Shares Out 307.93M
Stochastic %K 21%
Beta 0.54
Analysts Strong Sell
Price Target $16.60

Company Profile

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering novel medicines for rare diseases in the United States and internationally. The company's commercial product and product candidates consist of Galafold, an orally administered monotherapy for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, a novel two-component treatment program for adults living with...

Industry: Biotechnology
Sector: Healthcare
Phone: 609 662 2000
Fax: 609 662 2001
Address:
47 Hulfish Street, Princeton, United States
kaimckenzie05
kaimckenzie05 Jun. 26 at 5:04 PM
1 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Jun. 25 at 2:57 PM
$SNDX trades for 0.10X cumulative 10-year analyst consensus revenue estimates. Attached you will note 14 SNDX peers were acquired @ 10-year revenue multiples of 0.26X to 0.78X with most being acquired @ 0.33X to 0.41X 10-year revenues. This suggests SNDX's market cap would more than triple if SNDX is worth a peer 10-year revenue multiple of 0.33X (the lower end of the peer group). This is interesting because, since SNDX does not record Niktimvo related revenues, the 0.10X multiple does not consider any Niktimvo valuation nor SNDX's $600MM cash in the bank. This is another reason we believe the SNDX risk/reward profile is compelling. If Revumenib's M&A valuation is triple SNDX's market cap (assuming revenue estimates are credible & assuming Revumenib is worth a peer multiple...2 BIG IFS) then SNDX management & BOD are eventually obligated to consider a sale so shareholder value is truly maximized. Of course we could be wrong. This is not investment advice. Next up $DAWN $TARS $FOLD $KURA
2 · Reply
DonCorleone77
DonCorleone77 Jun. 25 at 11:11 AM
$FOLD Amicus announces approval of Pombiliti + Opfolda in Japan Amicus Therapeutics announced that Japan's Ministry of Health, Labour and Welfare, MHLW, has approved Pombiliti + Opfolda for the treatment of adult patients with late-onset Pompe disease, LOPD. "We are delighted that we will now be able to offer a compelling new treatment option to patients living with late-onset Pompe disease in Japan. We are grateful to the MHLW and to Japan's Pompe community, including the patients, families, and physicians who participated in our clinical studies, for their collaboration," said Bradley Campbell, President and Chief Executive Officer, Amicus Therapeutics, Inc.
0 · Reply
Stmkr
Stmkr Jun. 25 at 5:00 AM
$FOLD @valueforme I value your opinion a lot but I struggle to see why you don"t consider gene therapies (e.g. $SGMO) a threat to ERT and migalastat. (1) ERT requires repeated IV administration (2) Migalastat is oral but with some limitations; e.g. it should be taken without consuming food or caffeine two hours before and two hours after each dose to give a minimum four hour fast. It also only indicated for very specific subset of patients. (3) SGMO data (e.g. positive vs negative eGFR slope) are better So what am I missing?
3 · Reply
Mikelonggggggggg
Mikelonggggggggg Jun. 24 at 7:34 PM
0 · Reply
Mikelonggggggggg
Mikelonggggggggg Jun. 24 at 5:52 PM
0 · Reply
LucindaCruz
LucindaCruz Jun. 24 at 1:24 PM
$MA $CLSK $DJT $FOLD ACCOUNT CHALLENGE UPDATE:~ Starting Balance:~ $3,700 Current Balance:~ $89,848 Goal: $100K by end of Jun. Watch out for our next alert!*';🚀 https://amazing-stocks-winning-trades-us-market.biotechstockalert.us/
0 · Reply
mike_swiss_r
mike_swiss_r Jun. 24 at 1:13 PM
$SGMO $FOLD These guys, what a bromance
0 · Reply
valueforme
valueforme Jun. 24 at 1:13 PM
$FOLD $SGMO ok ok..i need more coffee..But I don't want SGMO shares based on Fabry data even with slope being positive. Fabry, Pompe, Hemophilia A and B, all those rare diseases are decently controlled by existing treatment regiments, some are oral. No way AAV based gene therapies can achieve significant commercial adoption in such a setup. Look at BioMarin and their Roctavian commercial fiasco
3 · Reply
lpalmieri
lpalmieri Jun. 24 at 12:56 PM
0 · Reply
Latest News on FOLD
3 Oversold Biotech Names

Jan 13, 2025, 12:56 PM EST - 5 months ago

3 Oversold Biotech Names

AVDL JAZZ VKTX XBI


Amicus Therapeutics: Cheap Heading Into 2025

Dec 27, 2024, 1:33 PM EST - 6 months ago

Amicus Therapeutics: Cheap Heading Into 2025


3 Attractive Biotechs With Recent Positives

Oct 21, 2024, 4:17 PM EDT - 8 months ago

3 Attractive Biotechs With Recent Positives

EXEL MRK TEVA XBI


Amicus: Teva Settlement Clears Revenue Path Forward For Galafold

Oct 18, 2024, 3:47 PM EDT - 8 months ago

Amicus: Teva Settlement Clears Revenue Path Forward For Galafold


'Boring' Amicus Therapeutics Is Making Progress

Sep 29, 2024, 2:44 AM EDT - 9 months ago

'Boring' Amicus Therapeutics Is Making Progress


3 'Repeatable' Biotech Trades

Sep 25, 2024, 12:46 PM EDT - 9 months ago

3 'Repeatable' Biotech Trades

DVAX GSK NTLA XBI


kaimckenzie05
kaimckenzie05 Jun. 26 at 5:04 PM
1 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Jun. 25 at 2:57 PM
$SNDX trades for 0.10X cumulative 10-year analyst consensus revenue estimates. Attached you will note 14 SNDX peers were acquired @ 10-year revenue multiples of 0.26X to 0.78X with most being acquired @ 0.33X to 0.41X 10-year revenues. This suggests SNDX's market cap would more than triple if SNDX is worth a peer 10-year revenue multiple of 0.33X (the lower end of the peer group). This is interesting because, since SNDX does not record Niktimvo related revenues, the 0.10X multiple does not consider any Niktimvo valuation nor SNDX's $600MM cash in the bank. This is another reason we believe the SNDX risk/reward profile is compelling. If Revumenib's M&A valuation is triple SNDX's market cap (assuming revenue estimates are credible & assuming Revumenib is worth a peer multiple...2 BIG IFS) then SNDX management & BOD are eventually obligated to consider a sale so shareholder value is truly maximized. Of course we could be wrong. This is not investment advice. Next up $DAWN $TARS $FOLD $KURA
2 · Reply
DonCorleone77
DonCorleone77 Jun. 25 at 11:11 AM
$FOLD Amicus announces approval of Pombiliti + Opfolda in Japan Amicus Therapeutics announced that Japan's Ministry of Health, Labour and Welfare, MHLW, has approved Pombiliti + Opfolda for the treatment of adult patients with late-onset Pompe disease, LOPD. "We are delighted that we will now be able to offer a compelling new treatment option to patients living with late-onset Pompe disease in Japan. We are grateful to the MHLW and to Japan's Pompe community, including the patients, families, and physicians who participated in our clinical studies, for their collaboration," said Bradley Campbell, President and Chief Executive Officer, Amicus Therapeutics, Inc.
0 · Reply
Stmkr
Stmkr Jun. 25 at 5:00 AM
$FOLD @valueforme I value your opinion a lot but I struggle to see why you don"t consider gene therapies (e.g. $SGMO) a threat to ERT and migalastat. (1) ERT requires repeated IV administration (2) Migalastat is oral but with some limitations; e.g. it should be taken without consuming food or caffeine two hours before and two hours after each dose to give a minimum four hour fast. It also only indicated for very specific subset of patients. (3) SGMO data (e.g. positive vs negative eGFR slope) are better So what am I missing?
3 · Reply
Mikelonggggggggg
Mikelonggggggggg Jun. 24 at 7:34 PM
0 · Reply
Mikelonggggggggg
Mikelonggggggggg Jun. 24 at 5:52 PM
0 · Reply
LucindaCruz
LucindaCruz Jun. 24 at 1:24 PM
$MA $CLSK $DJT $FOLD ACCOUNT CHALLENGE UPDATE:~ Starting Balance:~ $3,700 Current Balance:~ $89,848 Goal: $100K by end of Jun. Watch out for our next alert!*';🚀 https://amazing-stocks-winning-trades-us-market.biotechstockalert.us/
0 · Reply
mike_swiss_r
mike_swiss_r Jun. 24 at 1:13 PM
$SGMO $FOLD These guys, what a bromance
0 · Reply
valueforme
valueforme Jun. 24 at 1:13 PM
$FOLD $SGMO ok ok..i need more coffee..But I don't want SGMO shares based on Fabry data even with slope being positive. Fabry, Pompe, Hemophilia A and B, all those rare diseases are decently controlled by existing treatment regiments, some are oral. No way AAV based gene therapies can achieve significant commercial adoption in such a setup. Look at BioMarin and their Roctavian commercial fiasco
3 · Reply
lpalmieri
lpalmieri Jun. 24 at 12:56 PM
0 · Reply
EddieH2020
EddieH2020 Jun. 24 at 12:53 PM
$FOLD $SGMO Lol bodied that fool
0 · Reply
DoctrBenway
DoctrBenway Jun. 24 at 12:41 PM
$FOLD $SGMO Galafold has a decline in kidney function (GFR) over time while an increase (positive slope) is shown in the $SGMO data. Galafold "mean annualized eGFR slope: -0.4 mL/min/1.73m2/year (95% CI: -2.27, 1.48) (Source: Hughes, 2016:"
1 · Reply
valueforme
valueforme Jun. 24 at 12:37 PM
$FOLD $SGMO Very end of theor PR
0 · Reply
biotech
biotech Jun. 24 at 12:34 PM
$SGMO +1.74 mL #gain of kidney function ... VS #losing kidney funktion with $TAK Replagal (agalsidase alfa), $SNY Fabrazyme (agalsidase beta) and $FOLD Galafold (migalastat) marketed treatment options range from -2.2 to -0.4 mL/min/1.73m2/year
0 · Reply
gourmetturtle
gourmetturtle Jun. 24 at 12:29 PM
$FOLD $SGMO they will not. This stock probably won’t even see 50 cents again
0 · Reply
valueforme
valueforme Jun. 24 at 12:28 PM
$SGMO Sooo... How are they going to compete commercially with $FOLD with such eFGR slope data? Buying more FOLD https://investor.sangamo.com/news-releases/news-release-details/sangamo-therapeutics-announces-positive-topline-results
7 · Reply
BalaBioResearch
BalaBioResearch Jun. 21 at 10:47 PM
$FOLD Amicus Therapeutics, a Rare Disease Biotech Approaching Profitability With 2 Potential Blockbusters Priced for Commercial Failure https://x.com/BalaBioResearch/status/1936556305453555917
0 · Reply
valueforme
valueforme Jun. 20 at 10:48 PM
$FOLD Manufacturing setup - anticipating minimal impact from tarrifs
0 · Reply
valueforme
valueforme Jun. 20 at 10:45 PM
$FOLD Very important to understand this dynamics in Pompe. Switching of patients to the new therapy is a desicion that physicians make no more frequently than once per 2 years. Sanofi' s fabrazyme+nexviazyme revenue in q1 2025 is around €450 million. Basically a €2B annual market in Pompe . Acceleration of patient switching FOLD's Pom+Op is a matter of time. Watch Sanofi earnings
0 · Reply
valueforme
valueforme Jun. 20 at 10:23 PM
$FOLD Pom+Op revenue of Q2 might be much better that street expects. And because a very large chunk is ex-US, it's tough to rely on things like IQVIA for tracking. I accumulated decent position here, but might add a bit more before Q2 earnings call
0 · Reply
valueforme
valueforme Jun. 20 at 9:34 PM
$FOLD It was quite a rebalancing .
1 · Reply
CliffordCapital
CliffordCapital Jun. 20 at 7:13 PM
$FOLD $PLX @OldManLogan bringing up Amicus and I did some digging.. Amicus is valued at 1.7B.. they‘re expected to bring in 81M $ in 2026 (profit!). With my conservative calculation I have 80M $ profit for $PLX around 2030… if plx get‘s the same valuation we should be trading at 19$ lol….
3 · Reply